Aridis Pharmaceuticals, Inc.

ARDS • Biotechnology

$0.00

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 sept 2023

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$3,742.894

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Liquidez débil · 0.32Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 sept 2023, 12:00 a.m. UTCÚltima actualización de earnings: 6 nov 2023, 12:00 a.m. UTCÚltima actualización del perfil: 2 sept 2026, 12:20 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.00

Change0.00%

Shares Out37.43M

Market Cap$3.74K

Enterprise Value$3.38M

Beta0.76

P/E-0.00

P/S0.00

P/B-0.00

P/FCF-0.00

EV/Sales0.17

EV/EBITDA-5.89

Price$0.00

Change0.00%

Shares Out37.43M

Market Cap$3.74K

Enterprise Value$3.38M

Beta0.76

P/E-0.00

P/S0.00

P/B-0.00

P/FCF-0.00

EV/Sales0.17

EV/EBITDA-5.89

EV/FCF-0.19

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-0.25

Current Ratio0.32

Quick Ratio0.32

Revenue 5Y-100.00%

Volume10.00

Avg Volume14.79K

EPS Surprise0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

20/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

50/100

Por qué este puntaje▼

Liquidez débil · 0.32Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

ARDS

Analyst sentiment

Based on 7 analyst votes · 2026-09-05

93/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 8/14/2018

Industria: Biotechnology

P/B i: -0.00

Deuda / Patrimonio i: -0.25

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje4 / 20

Deuda / Patrimonio: -0.25

Ratio corriente: 0.32

Ratio rápido: 0.32

Estado: HighRisk

Advertencias

Weak Liquidity
Weak quick ratio

Transacciones internas

Actividad reciente de ejecutivos e insiders

Jafri Hasan

Transacción: 06/27/2024

COMPRA

Cambio

+250,000

Precio

$0.06

Presentación

06/28/2024

Tipo

COMPRA

HAMILTON JOHN F

Transacción: 06/27/2024

COMPRA

Cambio

+200,000

Precio

$0.06

Presentación

06/28/2024

Tipo

COMPRA

Windham-Bannister Susan Richards

Transacción: 06/27/2024

COMPRA

Cambio

+200,000

Precio

$0.06

Presentación

06/28/2024

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Jafri Hasan	COMPRA	+250,000	$0.06	06/27/2024	06/28/2024
HAMILTON JOHN F	COMPRA	+200,000	$0.06	06/27/2024	06/28/2024
Windham-Bannister Susan Richards	COMPRA	+200,000	$0.06	06/27/2024	06/28/2024
Truong Vu	COMPRA	+714,286	$0.07	06/24/2024	06/28/2024
Patzer Eric	COMPRA	+714,286	$0.07	06/24/2024	06/28/2024
Jafri Hasan	COMPRA	+20,000	$0.08	09/18/2023	09/19/2023
Truong Vu	COMPRA	+30,000	$0.08	09/18/2023	09/19/2023
Patzer Eric	COMPRA	+15,000	$0.08	09/18/2023	09/19/2023
Windham-Bannister Susan Richards	COMPRA	+15,000	$0.08	09/18/2023	09/19/2023
HAMILTON JOHN F	COMPRA	+15,000	$0.08	09/18/2023	09/19/2023
KURLAND FRED	COMPRA	+4,000	Not reported	06/05/2023	06/15/2023
KURLAND FRED	VENTA	-4,000	Not reported	06/05/2023	06/15/2023
Jafri Hasan	VENTA	-10,000	Not reported	06/05/2023	06/15/2023
Jafri Hasan	COMPRA	+10,000	Not reported	06/05/2023	06/15/2023
Windham-Bannister Susan Richards	COMPRA	+5,000	Not reported	06/05/2023	06/15/2023
Windham-Bannister Susan Richards	VENTA	-5,000	Not reported	06/05/2023	06/15/2023
Truong Vu	VENTA	-15,000	Not reported	06/05/2023	06/15/2023
Truong Vu	COMPRA	+15,000	Not reported	06/05/2023	06/15/2023
HAMILTON JOHN F	VENTA	-5,000	Not reported	06/05/2023	06/15/2023
HAMILTON JOHN F	COMPRA	+5,000	Not reported	06/05/2023	06/15/2023

Sobre la compañía

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.

Fuente - Link

Competidores

AFIB BTAX EVLO HSTC ICCT INFIQ LIFS STAB TCLIF TRVN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

📰

No hay noticias disponibles ahora

Vuelve a revisar más tarde.

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2023-11-06	-0.1	-0.02	0.08
2023-03-29	-0.41	-0.35017	0.05983
2022-11-21	-0.15192	-0.42	-0.26808
2022-08-16	-0.06	-0.45	-0.39
2022-05-16	-0.51	-0.44	0.07
2022-03-31	-0.58	-0.92	-0.34
2021-11-10	-0.54	-1.94	-1.4
2021-08-12	-0.57	-0.55	0.02
2021-05-11	-0.6	-0.77	-0.17
2021-03-30	-0.54	-0.59	-0.05
2020-11-20	-0.55	-0.65	-0.1
2020-08-11	-0.72	-0.47	0.25